These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17195185)

  • 1. Treatment of pulmonary fibrosis in systemic sclerosis: light at the end of the tunnel?
    Wollheim FA
    Arthritis Rheum; 2007 Jan; 56(1):9-12. PubMed ID: 17195185
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis.
    Bibi Y; Gottlieb AB
    J Am Acad Dermatol; 2008 Oct; 59(4):654-8. PubMed ID: 18571768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
    Distler JH; Distler O
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib as a novel therapeutic approach for fibrotic disorders.
    Distler JH; Distler O
    Rheumatology (Oxford); 2009 Jan; 48(1):2-4. PubMed ID: 19029132
    [No Abstract]   [Full Text] [Related]  

  • 6. Is imatinib mesylate a promising drug in systemic sclerosis?
    van Daele PL; Dik WA; Thio HB; van Hal PT; van Laar JA; Hooijkaas H; van Hagen PM
    Arthritis Rheum; 2008 Aug; 58(8):2549-52. PubMed ID: 18668570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SSc in 2011: From mechanisms to medicines.
    Mouthon L
    Nat Rev Rheumatol; 2012 Jan; 8(2):72-4. PubMed ID: 22231235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib for the treatment of refractory, diffuse systemic sclerosis.
    Sfikakis PP; Gorgoulis VG; Katsiari CG; Evangelou K; Kostopoulos C; Black CM
    Rheumatology (Oxford); 2008 May; 47(5):735-7. PubMed ID: 18326532
    [No Abstract]   [Full Text] [Related]  

  • 9. Imatinib mesylate treatment of nephrogenic systemic fibrosis.
    Kay J; High WA
    Arthritis Rheum; 2008 Aug; 58(8):2543-8. PubMed ID: 18668587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease.
    Distler JH; Manger B; Spriewald BM; Schett G; Distler O
    Arthritis Rheum; 2008 Aug; 58(8):2538-42. PubMed ID: 18668536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is IL-4 a potential therapeutic target in systemic sclerosis-associated pulmonary fibrosis?
    Sfikakis PP
    Clin Immunol; 2011 Dec; 141(3):240-1. PubMed ID: 21996458
    [No Abstract]   [Full Text] [Related]  

  • 12. Imatinib and the treatment of fibrosis: recent trials and tribulations.
    Gordon J; Spiera R
    Curr Rheumatol Rep; 2011 Feb; 13(1):51-8. PubMed ID: 21086081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis.
    Gordon JK; Spiera RF
    Curr Opin Rheumatol; 2010 Nov; 22(6):690-5. PubMed ID: 20827202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A new therapeutic avenue for severe systemic sclerosis: imatinib mesylate].
    Taïeb A; Constans J; Mahon FX
    Rev Med Interne; 2008 Mar; 29(3):173-5. PubMed ID: 17597261
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pulmonary hypertension: tailored treatment].
    Semeniuk GB
    Medicina (B Aires); 2007; 67(1):104. PubMed ID: 17410651
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study.
    Soria A; Cario-André M; Lepreux S; Rezvani HR; Pasquet JM; Pain C; Schaeverbeke T; Mahon FX; Taïeb A
    Dermatology; 2008; 216(2):109-17. PubMed ID: 18216472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.
    Iwamoto N; Distler JH; Distler O
    Curr Rheumatol Rep; 2011 Feb; 13(1):21-7. PubMed ID: 21042889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Where lies the blame for resistance--tumor or host?
    Sawyers CL
    Nat Med; 2007 Oct; 13(10):1144-5. PubMed ID: 17917659
    [No Abstract]   [Full Text] [Related]  

  • 19. Involvement of PDGF in fibrosis and scleroderma: recent insights from animal models and potential therapeutic opportunities.
    Iwayama T; Olson LE
    Curr Rheumatol Rep; 2013 Feb; 15(2):304. PubMed ID: 23307576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Idiopathic interstitial pneumonia: treatment].
    Cottin V
    Rev Mal Respir; 2006 Sep; 23(4 Pt 2):10S97-10S102. PubMed ID: 17127978
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.